Piper Sandler has initiated coverage on ANI Pharmaceuticals (ANIP), a specialty pharmaceutical firm, with an ‘Overweight’ rating and a price target of $68. The firm highlights ANI’s successful transformation from a generics-focused company to a leader in rare disease therapies, driven by the success of its lead asset, Cortrophin Gel.